Kinnate Biopharma Inc.
KNTEDelisted Apr 3, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001797768
Kinnate Biopharma Inc. was delisted on Apr 3, 2024; its insiders filed their last Form 4 on Apr 5, 2024; 56 institutions reported holding it in 13F filings for Q1 2024, worth $92.2M in total; Viking Global Investors was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kinnate Biopharma Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kinnate Biopharma Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| OrbiMed Advisors LLC | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Capital LLC | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Capital GP VIII LLC | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Advisors IV Ltd | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| OrbiMed Asia GP IV, L.P. | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Fund IV, L.P. | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Management IV, LLC | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Fund V, L.P. | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Opportunity Fund V, L.P. | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Management V, LLC | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Foresite Capital Opportunity Management V, LLC | 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Mitchell Dean J | Director | – | Apr 5, 2024 | 0 |
| Gordon Carl L | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Flaherty Keith T. | Director | 0 | Apr 5, 2024 | 0 |
| Tananbaum James B. | Director, 10% Owner | 0Indirect | Apr 5, 2024 | 0 |
| Smaldone Alsup Laurie | Director | – | Apr 5, 2024 | 0 |
| Sabzevari Helen | Director | – | Apr 5, 2024 | 0 |
| Meltz Mark A | COO GENERAL COUNSEL SECRETARY | 0 | Apr 5, 2024 | 0 |
| Epperly Melissa B, | Director | – | Apr 5, 2024 | 0 |
| Farzan Nima | CHIEF EXECUTIVE OFFICER | 0 | Apr 5, 2024 | 0 |
| Rome Michael E | Director | – | Apr 5, 2024 | 0 |
| Krishnamohan Neha | CHIEF FINANCIAL OFFICER | 0 | Apr 5, 2024 | 0 |
| DeSimone Jill | Director | – | Apr 5, 2024 | 0 |
| Williams Richard Thomas | CHIEF MEDICAL OFFICER | 67,588 | Mar 5, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 10, 2023 (view filing)5:42 PM ET | May 8 | 2 days | Foresite Capital Fund IV, L.P. and 5 others10% Owner | PPurchase | +1.78M | $2.80 | +$4.98M | New position520.7K after | 2 lotsDuplicate filing |
| May 10, 2023 (view filing) | May 8 | 2 days | Tananbaum James B.Director, 10% Owner | PPurchase | +1.78M | $2.80 | +$4.98M | New position520.7K after | 2 lots |
| May 8, 2023 (view filing)5:22 PM ET | May 4-5 | 4 days | OrbiMed Advisors LLC and 6 othersDirector, 10% Owner | PPurchase | +1.46M | $2.80 | +$4.09M | New position1.37M after | 5 lotsDuplicate filing |
| May 8, 2023 (view filing) | May 4-5 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.46M | $2.80 | +$4.09M | New position1.37M after | 5 lots |
| May 2, 2023 (view filing)9:34 PM ET | Apr 28-May 2 | 4 days | OrbiMed Advisors LLC and 6 othersDirector, 10% Owner | PPurchase | +1.41M | $2.61 | +$3.67M | New position794.4K after | 9 lotsDuplicate filing |
| May 2, 2023 (view filing) | Apr 28-May 2 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.41M | $2.61 | +$3.67M | New position794.4K after | 9 lots |
| Mar 15, 2022 (view filing) | Mar 11-14 | 4 days | Williams Richard ThomasChief Medical Officer | PPurchase | +40.0K | $8.47 | +$338.9K | +1,714.5%42.3K after | 2 lots |
| Feb 15, 2022 (view filing)9:42 PM ET | Feb 11-15 | 4 days | OrbiMed Advisors LLC and 3 othersDirector | PPurchase | +195.7K | $10.17 | +$1.99M | +5.9%3.51M after | 4 lotsDuplicate filing |
| Feb 15, 2022 (view filing) | Feb 11-15 | 4 days | Gordon Carl LDirector | PPurchase | +195.7K | $10.17 | +$1.99M | +5.9%3.51M after | 4 lots |